Eli Lilly’s Retatrutide Hits Record Weight Loss, Challenges Surgery Efficacy | Whalesbook
A new experimental weight-loss drug from Eli Lilly is generating excitement after delivering some of the most impressive results ever seen in a clinical trial for obesity treatment.
The drug, called retatrutide, helped participants lose up to 28.3% of their body weight over 80 weeks. In some cases, people lost as much as 85 pounds, bringing the results close to those typically seen with bariatric surgery.
Retatrutide is a once-weekly injectable medication currently being tested in Phase 3 clinical trials. Unlike popular medications such as Ozempic and Wegovy, which target the GLP-1 hormone receptor, retatrutide works on three different hormone receptors: GIP, GLP-1, and glucagon. This unique approach may explain its powerful weight-loss effects.
According to results from the TRIUMPH-1 trial, participants experienced the following average weight loss after 80 weeks:
- 4 mg dose: 19% body weight loss (about 47 pounds)
- 9 mg dose: 25.9% body weight loss (about 64 pounds)
- 12 mg dose: 28.3% body weight loss (about 70 pounds)
By comparison, participants who received a placebo lost only about 2.2% of their body weight, or roughly 5.5 pounds.
The results were even more striking among people with severe obesity. Participants who started with a Body Mass Index (BMI) of 35 or higher lost an average of 30.3% of their body weight, equivalent to around 85 pounds, after 104 weeks.
Experts say these findings suggest retatrutide could become one of the most effective obesity treatments available. Dr. Mir Ali, a bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center, described the drug as highly promising and potentially more effective than currently available medications.
Beyond weight loss, retatrutide also improved several important health markers linked to heart disease and metabolic health. Participants showed reductions in:
- Waist circumference
- Non-HDL cholesterol
- Triglycerides
- Blood pressure
- High-sensitivity C-reactive protein (hsCRP), a marker of inflammation
Researchers believe these improvements could help reduce the long-term health risks associated with obesity.
Like other medications in the GLP-1 family, retatrutide was associated with some side effects. The most commonly reported were:
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Upper respiratory infections
A small number of participants also experienced urinary tract infections (UTIs) and dysesthesia, a condition involving unusual skin sensations. Most side effects were mild to moderate, and many resolved during treatment.
While the results are highly encouraging, experts caution that more long-term studies are needed. Questions remain about long-term safety, availability, and insurance coverage. Since obesity is considered a chronic medical condition, patients may need ongoing treatment to maintain results.
For now, retatrutide represents a major step forward in obesity care and could become a powerful new option for people seeking significant and lasting weight loss.
#WeightLoss #ObesityTreatment #Retatrutide #EliLilly #HealthNews